A Macrolane Registry has been developed to facilitate the recording of all Macrolane procedures carried out in the UK.
Its purpose is to monitor the clinical effects and to report trends in the use of Macrolane. The Registry will allow for the uniform recording of all aspects of Macrolane treatments and demonstrates Q-Med’s commitment to patient safety and welfare, as well as conducting research on a continual basis. A UK breast study, comprising 50 patients, has received ethical committee approval and is underway. Further studies this year will commence on reconstructive use of Macrolane in the breast. There is currently an evaluation study, which commenced in January 2009, comparing use of autologous fat transfer to Macrolane in reconstructive patients. Macrolane is a hyaluronic acid gel used in non-surgical breast shaping procedures. It was launched last year, after seven years’ of research, and represents a significant advance in the use of hyaluronic acid for body shaping. The product is based on hyaluronic acid produced by Q-Med, the Swedish biotechnology company, using its unique, patented NASHA™ (stabilised non-animal hyaluronic acid) technology. Eighteen months on, the procedure is proving popular with nearly 3,000 procedures completed in a few select centres headed up by Q-Med certified cosmetic doctors and plastic surgeons. Whilst the safety of the gel is proven, further research is underway with the focus on improving treatment technique and treatment regimens.